Eric Siemers - Concepedia

Author

Eric Siemers

Also Known As

Brian A. Willis, David Shera, E SIEMERS, E Siemers, E. R. Siemers, E. Siemers, E.R. Siemers, ERIC R. SIEMERS, Eric R Siemers, Eric R. Siemers

256

Publications

35.3K

Citations

H-Index

124

Concepts

All Affiliations

Eli Lilly (United States)Indiana University – Purdue University Indianapolis Indiana University School of Medicine University of California San Diego Alzheimer's Association

About

Eric Siemers is an author at Eli Lilly (United States) specializing in medicine, neurology, and alzheimer's disease.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	22	32	1.9K
2	Health Sciences	10	10	531
3	Engineering	1	1	32
4	Management	1	1	146
5	Nursing	1	1	44

Eric Siemers

Publications

21.5K

Citations

H-Index

Page 1

	Year	Citations
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Reisa A. Sperling, Paul Aisen, Laurel Beckett, Alzheimer s & Dementia	2011	7K
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects Leslie M. Shaw, Hugo Vanderstichele, Małgorzata Knapik-Czajka, Annals of Neurology	2009	2.1K
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup Clifford R. Jack, J. Scott Andrews, Thomas G. Beach, Alzheimer s & Dementia	2024	1.7K
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease Rachelle S. Doody, Ronald G. Thomas, Martin R. Farlow, New England Journal of Medicine	2014	1.6K
A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease Rachelle S. Doody, Rema Raman, Martin R. Farlow, New England Journal of Medicine	2013	1.2K
Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease Lawrence S. Honig, Bruno Vellas, Merçé Boada, New England Journal of Medicine	2018	1K
Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients Eric Siemers, Karen Sundell, Christopher Carlson, Alzheimer s & Dementia	2015	362
Practice effects and the use of alternate forms in serial neuropsychological testing Leigh J. Beglinger, Brenda Gaydos, Kevin Duff, Archives of Clinical Neuropsychology NeuropsychologyPsychopharmacologyCognitive RehabilitationSocial SciencesPsychology	2005	358
Rate of functional decline in Huntington’s disease Karen Marder, Hongqing Zhao, Richard H. Myers, Neurology	2000	354
Phase 2 Safety Trial Targeting Amyloid β Production With a γ-Secretase Inhibitor in Alzheimer Disease Adam Fleisher, Rema Raman, Eric Siemers, Archives of Neurology	2008	331

Page 1